AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$CORT

Vieira Roberto Wandenkolk sold $6.5M of CORT

Vieira Roberto Wandenkolk (President, Oncology) sold 58,333 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $110.76 ($109.35–$115.44, $6.46M total) across 7 trades on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Vieira Roberto Wandenkolk
Published Sep 4, 2026, 1:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The disclosed sale is a routine 10b5‑1 transaction, offering limited new information for traders.

02

Market read

Routine insider sale with modest size; minimal impact on broader market.

03

What to watch

Potential upcoming clinical data releases could offset any negative sentiment from the insider sale.

Relevance 5/10Novelty 4/10Timing: filing reported Sep 3, 2026 (after‑market)

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

President of Oncology sold 58,333 shares for $6.46M via a 10b5‑1 plan on Sep 2, 2026.

Expected impact

minor downward pressure, limited to short‑term volatility

Evidence & confidence

Sale size is modest relative to market cap and follows a 10b5‑1 plan, suggesting no urgent information asymmetry.

Market effects

Sector

Limited; reflects routine insider activity in biotech sector.

Regional

None

Global

None

Counterpoint

What could challenge this read

Despite the sale, the company's pipeline may still drive upside.

Key entities

  • Company
    Corcept Therapeutics Inc.

    Biopharma focused on cortisol‑related therapies.

  • Insider
    Vieira Roberto Wandenkolk

    President, Oncology at Corcept Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CORT insider trading history →

Related articles

OCT 26
$CORTHighAI 8/10

Why is Corcept Therapeutics stock rallying today?

Corcept Therapeutics (CORT) stock rose 3.7% in pre-market trading after reporting positive Phase 2 BELLA trial results for Lifyorli in combination with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer. The study showed improved median progression-free survival (7.2 months) and objective response rate (59%) compared to the two-drug combination. The stock had previously declined 29.6% due to competitive concerns from Genmab's trial results.

investing.com2 min
OCT 23
$CORTHighAI 8/10

Corcept Therapeutics (CORT) Shares Drop 20% on Genmab's Phase 3

Corcept Therapeutics (CORT) shares dropped 20% to $85.86 after Genmab's phase 3 trial for a competing ovarian cancer drug succeeded, raising concerns about market competition. CORT's GF Value™ suggests it is 11.2% overvalued, while its GF Score™ is 85/100, indicating strong financial health. Insiders have sold $101.5M in shares over the past year, signaling caution.

gurufocus.com3 min
OCT 23
$CORTHighAI 8/10

Why is Corcept Therapeutics stock tumbling today?

Corcept Therapeutics (CORT) shares fell 12.9% after Genmab's rival drug showed positive results in a Phase 3 trial for platinum-resistant ovarian cancer, directly competing with Corcept's Lifyorli. The decline was exacerbated by prior downgrades and market headwinds, with shares dropping from $106.05 to a low of $90.99 before partially recovering to $93.68.

investing.com2 min
SEP 22
$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

insidermonkey.com3 min